Novartis Suspends Two Cancer Therapies Over Quality Concerns

Novartis said on Thursday it had temporarily suspended the production of its Lutathera and Pluvicto cancer therapies at facilities in Italy and New Jersey after potential quality issues were discovered in their manufacturing.
Reuters Health Information

source https://www.medscape.com/viewarticle/973496?src=rss

Comments

Popular posts from this blog

Student Nurses Who Refuse Vaccination Struggle to Complete Degrees

The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors